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ess: iyoshino@surg2.meSummary Background: In non-small cell lung cancer, a loss of heterozygosity (LOH)
is frequently observed; however, few studies have investigated the differences in the
LOH status between adenocarcinoma and squamous cell carcinoma.
Patients and methods: In a consecutive series of 49 patients with adenocarci-
nomas and 22 patients with squamous cell carcinomas, the LOH in tumors was
analyzed using polymerase chain reaction employing 5 fluorescence-labeled
dinucleotide markers (D2S123, D5S107, D10S197, D11SS904, D13S175) and an
autosequencer.
Results: LOH was more frequently observed in squamous cell carcinoma (20 of 22,
90%) than in adenocarcinomas (33 of 49, 67%) (P ¼ 0:0348), and the number of LOH
per patient was also higher in the patients with squamous cell carcinoma (2.271.4)
than in those with adenocarcinoma (1.571.2, P ¼ 0:037). In adenocarcinomas, the
number of LOH per patients correlated significantly with the pack-year index,
whereas the pathological stage significantly affected the number of LOH in squamous
cell carcinomas.
Conclusion: The presence of LOH is relatively uncommon in adenocarcinoma of
the lung; however, the incidence of LOH tends to be associated with the smoking
status.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
2-642-5466; fax: +81-92-
d.kyushu-u.ac.jpIntroduction
The incidence and mortality associated with lung
cancer have both increased worldwide during theed.
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LOH in NSCLC 309last several decades.1,2 The main reason for the
increase in mortality due to lung cancer lies in the
increase in the number of tobacco smokers.3–5 Loss
of heterozygosity (LOH) has been reported to be a
basic genetic disorder for carcinogenesis which
causes allelic losses at specific chromosomal loci of
several recessive oncogenes (e.g., the FHIT gene at
3p14,6 the p53 gene at 17p13,7,8 and the CDKN2 at
9p21).9 It was recently reported that a LOH at
chromosomes 3p14, 9p21, and 17p13 was fre-
quently observed in the bronchial epithelium of
smokers,10 and that the frequency of LOH was
significantly associated with the incidence of
carcinoma in situ.11 Therefore, it is possible that
the incidence of central-type lung cancer, mainly
squamous cell carcinoma, might potentially be
predicted by the frequency of LOH in bronchial
epithelial cells.
In adenocarcinoma of the lung, the incidence of
LOH has been reported to be less frequent than in
squamous cell carcinoma,12 however, the clinical
significance of LOH is still unclear.
This study was conducted in order to elucidate
the relationship between the frequency of LOH and
clinicopathologic factors in lung adenocarcinoma in
comparison to the same findings for squamous cell
carcinoma.Patients and methods
Patients
During the period between April 2000 and Septem-
ber 2001, a consecutive series of 71 patients with
non-small cell lung cancer (NSCLC) underwent a
surgical resection at the Second Department of
Surgery, Kyushu University Hospital. The histologic
diagnosis of the tumors was based on the criteria of
the World Health Organization,13 and the TNM stage
was determined according to the criteria revised inTable 1 Status of LOH and smoking in both types of lun
Factors Aden
Age 65.57
Male/female 23/2
Pathological state
I 40 (8
II 3 (6.
III 6 (12
Number of patients with at least one LOH 33 (6
Mean number of LOH per patient 1.57
PYI 15.87
aAdeno, adenocarcinoma; Squ, squamous cell carcinoma.1997.14 They included 49 adenocarcinomas and 22
squamous cell carcinomas. The age and gender
distribution for each cell type is summarized in
Table 1. Written informed consent was obtained
from each patient to permit the study of excised
tissue from surgical specimens. The Institutional
Review Board of our university also gave its
approval.
Extraction of genomic DNA from specimens
Both cancer tissue and the corresponding normal
lung tissue were obtained from surgical specimens
immediately after resection. The tissue specimens
were placed in liquid nitrogen until used for
analysis. The remaining specimens were routinely
processed for histological examinations. Frozen
tissue specimens were broken up in liquid nitrogen
and lysed in digestion buffer (10mM Tris–HCl; pH
8.0,0.1M EDTA; pH 8.0, 0.5% SDS, 20 mg/ml para-
creatic RNase). After treatment with proteinase K
and extraction with phenol, DNA was precipitated
with ethanol, and then it was dissolved in 1TE
(10mM Tris-Cl (pH 7.5), 1mM EDTA).
High resolution fluorescent microsatellite
analysis (HRFMA)
Five dinucleotide microsatellites, D2S123, D5S107,
D10S197, D11S904 and D13S175 were used as
markers for analysis of MSI and LOH.15 Using
genomic DNA derived from tissue specimens, the
5 microsatellite sequences were amplified by
polymerase chain reaction (PCR). Oligonucleotide
primers corresponding to the microsatellite se-
quences15 were synthesized and purified using high
performance liquid chromatography. 50 primers
were labeled with the fluorescent compound, ROX
(6-carboxy-x-rhodamine) or HEX (6-carboxy-20, 40,
70, 4, 7-hexachloro-fluorescein). PCR reactions
were performed using TAKARA Taq Reagent Kitsg cancer.
oa (N ¼ 49) Squ (N ¼ 22) P-value
11.0 66.278.1 0.78
6 20/2 o0.01
1.6%) 8 (36.4%)
1%) 7 (31.8%)
.2%) 7 (31.8%) o0.01
7%) 20 (90%) 0.03
1.4 2.271.2 0.037
23.3 51.7732.3 o0.01
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in the Perkin–Elmer GeneAmp PCR system 9600 or
2400 (Norwalk, CT). Each 50 ml reaction mixture
contained 1x reaction buffer, 350 mM of each dNTP,
10 pmol of each primer, 2.5 U of the polymerase,
and 25 mg of the genomic DNA. The thermal
conditions of the system were as follows: one cycle
at 95 1C for 4min, 35 cycles at 95 1C for 0.5min,
55 1C for 0.5min, 72 1C for 0.5min, one cycle at
72 1C for 10min. Next 0.5 U of T4DNA polymerase
was added to the mixture, followed by incubation
at 37 1C for 10min. Each 1.5 ml product was mixed
with 0.5 ml loading buffer (blue dextran, 25mM
EDTA), 2.5 ml of formamide, and 0.5 ml of dH2O. To
compare the electrophoretic profiles of the two
samples, 1.2ml of ROX-labeled product and 0.3ml
HEX-labeled product were mixed together. Samples
were denatured and loaded onto ABI 373A sequen-
cer (Applied Biosystems, Foster City, CA). In each
case, a size marker labeled with TMRA (N,N,N0,N0-
tetramethyl-6-carboxyrhodamine) was always elec-
trophoresed in each lane in order to standarize the
mobility of the sample. The running conditions
were 1500 V, 20mA, and 30W for 5.5 h. The data
were processed using the ABI software package
from GeneScan (Applied Biosystems).Detection of LOH
The method of detecting microsatellite alteration
including microsatellite instability and LOH used
herein has been described previously.15 Briefly, for
the detection of LOH, the fluorescence of a peak
decreased more than that of the normal control
when the LOH occurred in the amplified region ofFigure 1 Detection of LOH. The fluorescence (y-axis) of tw
normal tissues, regarding the amplified product derived from t
Green line and orange line represent normal tissue and tumothe genomic DNA derived from tumor tissue speci-
mens as shown in Fig. 1.
Statistical analysis
The number of LOH detected among the 5 markers
was compared among the subgroups, which were
divided according to clinicopathologic factors, and
differences were analyzed using Student’s t-test.
Each statistical difference was determined to be
significant when the P-value was below 0.05. The
correlation between the number of LOH and the
pack-year index (PYI) was analyzed using Spear-
man’s test.Results
Differences in the clinicopathologic factors includ-
ing the LOH status for the two cell types are
summarized in Table 1. The proportion of cases in
which LOH was detected by at least one out of the 5
markers was significantly lower in adenocarcinomas
(33 of 49, 67%) than in squamous cell carcinomas
(20 of 22, 90%) (P ¼ 0:03). The mean number of
LOH per patient was also lower in adenocarcinomas
(1.571.4) than in squamous cell carcinomas
(2.271.2) (P ¼ 0:04). In patients with adenocarci-
nomas, the proportions of male patients and those
with stage II/III disease, and the value of PYI (PYI
means a value calculated with a formula: the
number of cigarette packs per day divided by the
years of smoking) were significantly lower.
Next, we investigated whether the differences in
such factors affect any differences in the frequencyo peaks at bp 210 and 213 decreased more than that in
he genomic DNA of tumor tissue using the marker D2S123.
r tissue, respectively.
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carcinomas. In patients with adenocarcinoma, the
number of LOH showed a significantly higher
increase with a high PYI (Table 2). The number of
LOH for 10 heavy smokers (2.372.90) was signifi-
cantly higher than in 28 non-smokers (1.17871.19)
(P ¼ 0:03). No significant differences in the number
of LOH for the subgroups divided by gender and
pathological stage were observed. In patients with
squamous cell carcinoma, those with stage IA
disease showed a significantly lower number of
LOH (1.0070.82) than the other stages (stage IB or
more) (2.4471.10), whereas no differences were
observed among the subgroups divided by gender
and PYI (Table 3).Discussion
In previous studies analyzing LOH in the tumor
suppresser genes such as FHIT (3p14), p53 (17p13),Table 2 The relationship between the frequency
of LOH and other clinicopathologic factors in
adenocarcinomas.
Variables Number of LOH P-value
Gender
Male (N ¼ 23) 1.5771.27 0.65
Female (N ¼ 26) 1.3971.45
Pathological stage
IA (N ¼ 33) 1.2771.23 0.15
Othersa (N ¼ 16) 1.8871.50
PYI 0 (N ¼ 28) 1.1871.19 0.03
Less than 40 (N ¼ 11) 1.4671.29
40 or more (N ¼ 10) 2.3072.90
aOthers included 7 stage IB, 1IIA, 2IIB and 6 IIIA
(2T1N2M0 and 4T2N2M0).
Table 3 The relationship between the frequency
of LOH and other clinicopathologic factors in
squamous cell carcinomas.
Variables Number of LOH P-value
Gender
Male (N ¼ 20) 2.5073.54 0.70
Female (N ¼ 2) 2.1570.93
Pathological stage
IA (n ¼ 4) 1.0070.82 0.02
Othersa (N ¼ 18) 2.4471.10
PYI Less than 50 (N ¼ 12) 2.0871.17 0.68
50 or more (N ¼ 10) 2.3071.10
aOthers included 4 stage IB, 3IIA, 4IIB 7 IIIA (1T1N2M0,
4T2N2M0 and 1T3N1M0).CDKN2 (9p21), hMLH1 (3p21.3), or hMSH3 (5q11-
13), the association between the incidence of LOH
and tobacco exposure has been demonstrated in
the bronchial epithelium of non-cancer bearing
individuals and in lung cancer tissues.10,12,16,17
Regarding adenocarcinomas, which arise from the
peripheral airway, relative risk is actually asso-
ciated with cigarette smoking although the risk is
relatively lower than that seen in squamous cell
carcinomas18,19 although little is known about the
relationship between smoking and genetic altera-
tions in pneumocytes. The purpose of the present
study was to elucidate any differences, in the LOH
status between adenocarcinoma and squamous cell
carcinoma, and to determine whether the inci-
dence of LOH in adenocarcinoma was associated
with the degree of tobacco exposure, using a
unique automatic fluorescent system.
Squamous cell carcinomas clearly showed a
higher incidence of LOH, and a higher number of
LOH per patient than did adenocarcinomas. This
finding was not inconsistent with the results of a
previous report,12 and one reason for this differ-
ence might be due to different levels of tobacco
smoking (PYI) among the patients with the two cell
types. However, a positive correlation between the
PYI and the frequency of the LOH was observed in
adenocarcinoma but not in squamous cell carcino-
ma. In patients with lung adenocarcinoma, smoking
must also be a risk factor for carcinogenesis. The
mean number of LOH in patients with adenocarci-
noma and heavy smokers (2.3) was comparable to
that of patients with squamous cell carcinoma
(2.2), most of whom were smokers. The incidence
of LOH was therefore strongly influenced by
tobacco smoking.
In this study, the incidence of LOH in adenocar-
cinoma was lower than in squamous cell carcinomas
(67% vs. 90%, P=0.03). This suggests that mechan-
isms other than LOH may also play some role in
genetic disorder or the regulation of protein
expression. An abnormality of mismatch repair
enzymes has been reported to be a major cause
of carcinogenesis in colorectal cancer.20 Our detec-
tion system for the microalteration of genes also
demonstrated microsatellite instability,21 which
may reflect a mismatch repair disorder; however,
only 2 patients out of the 49 adenocarcinomas
showed microsatellite instability in this study (data
not shown). Recently, methylation of promotor
regions for tumor suppressor genes has attracted
attention as a possible cause of several types of
cancers.22 In lung adenocarcinoma, such a genetic
disorder should thus be examined in this future.
More recently, Powell et al.23 reported that LOH
of 3p, 8p, 9p, 10p and 18q in lung adenocarcinoma
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than in smokers, thus suggesting that lung carcino-
genesis differs in among nonsmokers and smokers.
The reason for such inconsistency between their
results and ours might be due to the fact that the
markers and detection system used by them were
different from those in the present study.
In conclusion, the presence of LOH was less
common in adenocarcinoma than in squamous cell
carcinoma of the lung, however, its occurrence was
significantly affected by a patient’s tobacco smok-
ing history for both types of lung cancer.References
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